ProCE Banner Activity

SWORD-1 and -2: Durable Virologic Efficacy Through Week 100 With Switch From Baseline ART to DTG Plus RPV in Virologically Suppressed Patients

Capsule Summary
Conference Coverage

Observations from patients with delayed switch to DTG plus RPV at Week 52 confirm safety and efficacy findings of primary analysis.

Released: July 31, 2018

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

Janssen

ViiV Healthcare

Partners

AIDS 2018

ProCE Banner

IAS 2018

ProCE Banner